Want to see GLMD full AI Analyst Report?
GLMD Stock Chart & Stats
$4.30
$0.01(2.75%)
At close: 4:00 PM EDT
$4.30
$0.01(2.75%)
Day’s Range― - ―
52-Week Range$3.29 - $13.20
Previous Close$0.53
Volume60.58K
Average Volume (3M)39.70K
Market Cap
$4.04M
Enterprise Value-$11.64
Total Cash (Recent Filing)$11.39M
Total Debt (Recent Filing)$129.00K
Price to Earnings (P/E)―
Beta2.11
Next Earnings
May 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.82
Shares Outstanding1,041,565
10 Day Avg. Volume16,754
30 Day Avg. Volume39,696
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.51
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-12.48
Revenue Forecast (FY)$5.72M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageVery low debt limits interest and refinancing burdens, preserving financial flexibility relative to a more leveraged development-stage biotech. This supports the company’s ability to direct available capital toward research, clinical development, and strategic initiatives rather than debt service.
Colospan Platform ExpansionThe successful feasibility study provides early clinical support for Colospan’s colorectal surgery technology and expands Galmed beyond a single drug program. A broader device and biotech portfolio could create additional development and commercialization pathways if later studies and regulatory work succeed.
Differentiated Aramchol DeliveryImproved systemic and central-nervous-system exposure could make Aramchol more adaptable to new therapeutic applications, while the film addresses swallowing difficulty in Parkinson’s disease. This creates a potentially differentiated platform for future licensing or co-development.
Bears Say
Pre-revenue And Worsening LossesWith no product revenue, Galmed has no recurring commercial base to offset research and operating costs. The recent increase in net loss shows that development spending continues to pressure earnings, leaving the company dependent on successful clinical progress and future financing.
Increasing Cash Burn And Shrinking ResourcesHigher operating burn combined with a substantial decline in cash and liquid investments reduces the company’s financial runway. Continued development and commercialization efforts may therefore require additional external capital, increasing funding risk and potential dilution over the next several quarters.
Colospan Financial And Integration RiskThe acquisition adds a financially stressed business that requires meaningful follow-on investment before its commercial potential is established. Integration demands, operating losses, and the planned European commitment could consume scarce resources and amplify execution and capital-allocation risk.
Galmed Pharmaceuticals News
GLMD FAQ
What was Galmed Pharmaceuticals’s price range in the past 12 months?
Galmed Pharmaceuticals lowest stock price was $3.29 and its highest was $13.20 in the past 12 months.
What is Galmed Pharmaceuticals’s market cap?
Galmed Pharmaceuticals’s market cap is $4.04M.
When is Galmed Pharmaceuticals’s upcoming earnings report date?
Galmed Pharmaceuticals’s upcoming earnings report date is May 19, 2027 which is in 251 days.
How were Galmed Pharmaceuticals’s earnings last quarter?
Galmed Pharmaceuticals released its earnings results on May 20, 2026. The company reported -$0.38 earnings per share for the quarter.
Is Galmed Pharmaceuticals overvalued?
According to Wall Street analysts Galmed Pharmaceuticals’s price is currently Overvalued.
Does Galmed Pharmaceuticals pay dividends?
Galmed Pharmaceuticals does not currently pay dividends.
What is Galmed Pharmaceuticals’s EPS estimate?
Galmed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Galmed Pharmaceuticals have?
Galmed Pharmaceuticals has 1,041,565 shares outstanding.
What happened to Galmed Pharmaceuticals’s price movement after its last earnings report?
Galmed Pharmaceuticals reported an EPS of -$0.38 in its last earnings report. Following the earnings report the stock price went up 7.036%.
Which hedge fund is a major shareholder of Galmed Pharmaceuticals?
Currently, no hedge funds are holding shares in GLMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Technical Analysis
AIM ImmunoTech
―
Jaguar Animal Health
―
Quoin Pharmaceuticals
―
Silo Pharma
―
Calidi Biotherapeutics
―
Ownership Overview
―
Insiders
0.49% Mutual Funds
― Other Institutional Investors
99.51% Public Companies and
Individual Investors